See more : K Car Co., Ltd. (381970.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Eloxx Pharmaceuticals, Inc. (ELOX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eloxx Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Cisadane Sawit Raya Tbk (CSRA.JK) Income Statement Analysis – Financial Results
- NovaGold Resources Inc. (NG) Income Statement Analysis – Financial Results
- China Railway Group Limited (0390.HK) Income Statement Analysis – Financial Results
- Chalet Hotels Limited (CHALET.BO) Income Statement Analysis – Financial Results
- Epiroc AB (publ) (0YSU.L) Income Statement Analysis – Financial Results
Eloxx Pharmaceuticals, Inc. (ELOX)
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.00K | 75.00K | 100.00K | 0.00 | 200.00K | 0.00 | 140.00K | 275.00K | 456.67K | 300.00K | 66.67K | 125.00K | 16.67K | 10.00K | 200.00K | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -18.71K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.00K | 75.00K | 100.00K | 0.00 | 200.00K | 0.00 | 140.00K | 275.00K | 456.67K | 300.00K | 66.67K | 125.00K | 16.67K | 10.00K | 200.00K | 1.00 | 18.71K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 1,871,400.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.73M | 45.57M | 14.59M | 26.35M | 20.49M | 16.40M | 733.66K | 2.18M | 4.57M | 3.34M | 2.09M | 2.57M | 3.72M | 2.64M | 2.35M | 1.76M | 1.21M | 1.57M | 1.42M | 1.15M | 793.90K | 370.19K | 479.47K | 476.46K | 173.46K | 0.00 | 0.00 |
| General & Administrative | 10.69M | 20.45M | 14.85M | 24.21M | 26.48M | 2.70M | 1.46M | 1.41M | 2.74M | 2.61M | 2.10M | 2.26M | 2.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.34M | 1.40M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 151.72K | 574.35K | 0.00 | 0.00 | 0.00 |
| SG&A | 10.69M | 20.45M | 14.85M | 24.21M | 26.48M | 2.70M | 1.46M | 1.41M | 2.74M | 2.61M | 2.10M | 2.26M | 2.21M | 2.35M | 2.21M | 2.29M | 2.41M | 1.92M | 2.03M | 2.91M | 1.48M | 1.94M | 1.49M | 1.97M | 982.40K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -115.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.37K | -7.81K |
| Operating Expenses | 34.42M | 66.02M | 29.44M | 50.56M | 46.97M | 19.10M | 2.14M | 3.79M | 7.74M | 7.02M | 4.59M | 5.29M | 6.09M | 4.99M | 4.56M | 4.06M | 3.62M | 3.49M | 3.45M | 4.05M | 2.28M | 2.31M | 1.97M | 2.45M | 1.16M | -10.37K | -7.81K |
| Cost & Expenses | 34.42M | 66.02M | 29.44M | 50.56M | 46.97M | 19.10M | 2.14M | 3.79M | 7.74M | 7.02M | 4.59M | 5.29M | 6.09M | 4.99M | 4.56M | 4.06M | 3.62M | 3.49M | 3.45M | 4.05M | 2.28M | 2.31M | 1.97M | 2.45M | 1.16M | -10.37K | -7.81K |
| Interest Income | 274.00K | 8.00K | 337.00K | 1.07M | 601.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.48K | 0.00 | 0.00 | 43.08K | 100.45K | 69.30K | 0.00 | 54.03K | 0.00 | 0.00 | 24.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.95M | 1.26M | 1.41M | 1.62M | 7.00K | 43.00K | 265.20K | 533.00 | 2.77K | 77.44K | 119.09K | 134.55K | 88.12K | 610.67K | 1.01M | 434.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 695.00K | 960.00K | 571.00K | 559.00K | 216.00K | 39.00K | 44.08K | 93.39K | 177.07K | 349.66K | 293.63K | 258.02K | 143.27K | 126.57K | 111.75K | 96.85K | 166.17K | 40.11K | 43.72K | 30.42K | 38.70K | 24.36K | 24.16K | 18.71K | 4.00K | 0.00 | 0.00 |
| EBITDA | -33.37M | -66.02M | -33.46M | -50.56M | -46.15M | -20.39M | -4.59B | -8.85M | -17.88M | -8.80M | -4.65B | -4.83M | -6.33B | -4.72M | -4.17M | -3.50M | -3.15M | -3.38M | -3.28M | -4.01M | -2.23M | -2.09M | -1.95M | -2.43M | -1.15M | -10.37K | -7.81K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,827.52% | -9,982.48% | -6,572.38% | 0.00% | -2,491.85% | 0.00% | 2,290.26% | -1,343.62% | -620.45% | -1,051.61% | -5,068.89% | -2,853.45% | -25,703.22% | -23,608.61% | -1,120.21% | -200,724,000.00% | -242,873,500.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -34.42M | -66.02M | -33.46M | -50.56M | -47.57M | -20.39M | -4.59M | -11.19M | -18.08M | -9.15M | -4.65M | -5.41M | -7.92M | -4.85M | -4.28M | -3.60M | -3.32M | -3.42M | -3.32M | -4.04M | -2.27M | -2.11M | -1.97M | -2.45M | -1.16M | -10.37K | -7.81K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,926.64% | -24,102.31% | -9,147.80% | 0.00% | -2,705.76% | 0.00% | -3,461.80% | -1,558.07% | -788.11% | -1,107.00% | -5,129.06% | -2,657.39% | -24,223.34% | -22,686.06% | -1,057.12% | -197,107,000.00% | -244,744,800.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.65M | -709.00K | -1.12M | -319.00K | 502.00K | -824.00K | -2.24M | 2.25M | 12.95K | -77.44K | -1.47M | 345.40K | 649.73K | 4.85M | 4.28M | 3.60M | 3.32M | 3.42M | 1.13M | 959.02K | 130.95K | 150.55K | 60.33K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -36.07M | -66.73M | -34.58M | -50.87M | -47.06M | -21.21M | -6.84M | -8.95M | -18.06M | -9.23M | -6.12M | -5.07M | -7.27M | -12.77M | -4.76M | -4.27M | 0.00 | 0.00 | -3.03M | -3.76M | -2.14M | -1.96M | -1.91M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,930.57% | -24,085.05% | -9,225.23% | 0.00% | -2,533.07% | 0.00% | -9,123.46% | -1,731.89% | -934.55% | 0.00% | 0.00% | -2,426.36% | -22,560.92% | -21,376.54% | -981.84% | -191,073,900.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.26M | 1.41M | 1.62M | 122.00K | 43.00K | -1.04M | -680.00K | 2.77K | 77.44K | 119.09K | -24.26K | 1.07M | 8.54M | 1.44M | 1.00M | -69.30K | -104.46K | -342.82K | -310.35K | -202.27K | -174.81K | -94.08K | -2.53K | 13.14K | 10.37K | 7.81K |
| Net Income | -36.07M | -66.73M | -34.58M | -50.87M | -47.19M | -21.21M | -5.80M | -8.27M | -18.06M | -9.23M | -6.12M | -5.07M | -7.27M | -13.38M | -5.73M | -4.60M | -3.25M | -3.31M | -2.98M | -3.73M | -2.07M | -1.94M | -1.88M | -2.44M | -1.17M | -10.37K | -7.81K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,023.91% | -24,085.05% | -9,225.23% | 0.00% | -2,533.07% | 0.00% | -9,559.65% | -2,082.50% | -1,007.62% | -1,083.90% | -4,972.38% | -2,383.13% | -22,361.26% | -20,663.38% | -969.71% | -187,699,100.00% | -244,491,600.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.65 | -38.15 | -34.47 | -53.46 | -58.19 | -170.52 | -199.71 | -325.47 | -1.00K | -1.35K | -3.59K | -4.73K | -7.48K | -21.38K | -23.19K | -20.18K | -14.92K | -17.18K | -15.43K | -21.80K | -13.96K | -13.10K | -19.15K | -24.95K | -655.27 | -134.73 | -101.43 |
| EPS Diluted | -16.65 | -38.15 | -34.47 | -53.46 | -58.19 | -170.52 | -199.71 | -325.47 | -1.00K | -1.35K | -3.59K | -4.73K | -7.48K | -21.38K | -23.19K | -20.18K | -14.92K | -17.18K | -15.43K | -21.80K | -13.96K | -13.10K | -19.15K | -24.95K | -655.27 | -134.73 | -101.43 |
| Weighted Avg Shares Out | 2.17M | 1.75M | 1.00M | 951.58K | 810.91K | 124.41K | 29.02K | 25.40K | 18.02K | 6.85K | 1.71K | 1.07K | 972.00 | 626.00 | 247.00 | 228.00 | 218.00 | 193.00 | 193.00 | 171.00 | 148.00 | 148.00 | 98.00 | 98.00 | 1.78K | 77.00 | 77.00 |
| Weighted Avg Shares Out (Dil) | 2.17M | 1.75M | 1.00M | 951.58K | 810.91K | 124.41K | 29.02K | 25.40K | 18.02K | 6.85K | 1.71K | 1.07K | 972.00 | 626.00 | 247.00 | 228.00 | 218.00 | 193.00 | 193.00 | 171.00 | 148.00 | 148.00 | 98.00 | 98.00 | 1.78K | 77.00 | 77.00 |
ELOX Stock Price Increases Over 7% Pre-Market: Why It Happened
The stock price of Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) increased by over 7% pre-market. This is why it happened.
Are Options Traders Betting on a Big Move in Eloxx Pharmaceuticals (ELOX) Stock?
Investors need to pay close attention to Eloxx Pharmaceuticals (ELOX) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Eloxx (ELOX) Stock?
Investors need to pay close attention to Eloxx (ELOX) stock based on the movements in the options market lately.
Eloxx Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the closing of an underwritten public offering of 38,333,334 shares of common stock...
Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) Stock: Over 20% Decrease Explanation
The stock price of Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) decreased by over 20% during intraday trading. This is why it happened.
Eloxx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the pricing of an underwritten public offering of 33,333,334 shares of common stock...
Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update
Acquisition of Zikani Therapeutics, Ribosomal Modulation Company; Combined Company Advancing Ribosomal RNA-Targeted Genetic Therapies
Eloxx Pharmaceuticals (ELOX) Is in Oversold Territory: What's Next?
Eloxx Pharmaceuticals (ELOX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Eloxx Pharmaceuticals Stock Price Increased Over 15% Pre-Market: Why It Happened
The stock price of Eloxx Pharmaceuticals (NASDAQ: ELOX) increased by over 15% pre-market. This is why it happened.
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms
Source: https://incomestatements.info
Category: Stock Reports